Amosartan
1st fixed-dose combination drug introduced in Korea
Amosartan Q
Controls Hypertension and Dyslipidemia at single treatment
Amosartan Plus
Treatment to patient not adequately controlled on agent double combo FDCs
Rosuzet
Increased efficacy due to improved lipid level control
Gugutams
A novel treatment option for ED patients accompanied by BPH
Monterizine
40% of allergic rhinitis patients accompanied by asthma , 80% of asthma patients accompanied by allergic rhinitis
Hyalrheuma injection
CE certified by SGS as a class-3 medical device
Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs
Jan 19, 2021
'Hanmi presents solution package for coping with COVID-19, including the mass production of nucleic acid vaccines'
Jan 12, 2021
Hanmi Pharmaceutical and Merck Enter into Licensing Agreement to Develop Efinopegdutide
Sep 03, 2020